Intra-Cellular Therapies Inc
NASDAQ:ITCI

Watchlist Manager
Intra-Cellular Therapies Inc Logo
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Watchlist
Price: 85.69 USD -0.36% Market Closed
Market Cap: 9.1B USD
Have any thoughts about
Intra-Cellular Therapies Inc?
Write Note

Relative Value

The Relative Value of one ITCI stock under the Base Case scenario is 38.68 USD. Compared to the current market price of 85.69 USD, Intra-Cellular Therapies Inc is Overvalued by 55%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ITCI Relative Value
Base Case
38.68 USD
Overvaluation 55%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
76
vs Industry
11
Median 3Y
18.1
Median 5Y
35.3
Industry
2.5
Forward
13.2
vs History
vs Industry
Median 3Y
-25
Median 5Y
-15.1
Industry
21.9
Forward
-123.1
vs History
vs Industry
Median 3Y
-23
Median 5Y
-15.3
Industry
16.5
vs History
vs Industry
Median 3Y
-23
Median 5Y
-15.3
Industry
23.6
vs History
31
vs Industry
6
Median 3Y
7.9
Median 5Y
6.7
Industry
2.1
vs History
77
vs Industry
11
Median 3Y
15.8
Median 5Y
30.4
Industry
2.6
Forward
11.7
vs History
73
vs Industry
12
Median 3Y
17.1
Median 5Y
22
Industry
5.2
vs History
vs Industry
Median 3Y
-21.6
Median 5Y
-13
Industry
13.3
Forward
-72.5
vs History
vs Industry
Median 3Y
-21.6
Median 5Y
-13
Industry
16.6
Forward
-77.8
vs History
vs Industry
Median 3Y
-20.9
Median 5Y
-13.5
Industry
15.6
vs History
vs Industry
Median 3Y
-20.8
Median 5Y
-13.5
Industry
19.1
vs History
73
vs Industry
4
Median 3Y
27.8
Median 5Y
30.8
Industry
1.9

Multiples Across Competitors

ITCI Competitors Multiples
Intra-Cellular Therapies Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Intra-Cellular Therapies Inc
NASDAQ:ITCI
9.1B USD 14.8 -105.2 -66.7 -66.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
710.5B USD 17.4 84.9 45.7 51
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.3 27.8
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.3 25.4 12.3 16
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
202.7B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.3B CHF 4.1 11.6 10.1 14
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP 4.1 31.6 169.4 253.9
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
US
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Average P/E: 32.4
Negative Multiple: -105.2
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
84.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25.4
-22%
US
Merck & Co Inc
NYSE:MRK
20.7
7 321%
CH
Roche Holding AG
SIX:ROG
17.6
32%
CH
Novartis AG
SIX:NOVN
11.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.6
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Discover More
Back to Top